Related references
Note: Only part of the references are listed.The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
Jordan Berlin et al.
CLINICAL CANCER RESEARCH (2013)
Unraveling the therapeutic potential of the Hedgehog pathway in cancer
Dereck Amakye et al.
NATURE MEDICINE (2013)
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities
Mariella Gruber Filbin et al.
NATURE MEDICINE (2013)
A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
Stanley B. Kaye et al.
CLINICAL CANCER RESEARCH (2012)
Clinical Experience With Hedgehog Pathway Inhibitors
Jennifer A. Low et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Brief Report: Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449.
Charles M. Rudin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mechanisms of Hedgehog pathway activation in cancer and implications for therapy
Suzie J. Scales et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
A paracrine requirement for hedgehog signalling in cancer
Robert L. Yauch et al.
NATURE (2008)
Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma
Eli E. Bar et al.
STEM CELLS (2007)
The Gli code: an information nexus regulating cell fate, stemness and cancer
Ariel Ruiz i Altaba et al.
TRENDS IN CELL BIOLOGY (2007)
Targeting the Hedgehog pathway in cancer
Lee L. Rubin et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Distinct roles of PTCH2 splice variants in Hedgehog signalling
F Rahnama et al.
BIOCHEMICAL JOURNAL (2004)
Share Paper
